High rates of venous thromboembolic events in patients undergoing systemic therapy for urothelial carcinoma: A systematic review and meta-analysis
详细信息 查看全文
- 作者：Ajay Gopalakrishna ; M.S.a ; Thomas A. Longo ; M.D.a ; Joseph J. Fantony ; M.D.a ; Uma Doshi ; M.D.a ; Michael R. Harrison ; M.D.b ; Megan Van Noord ; M.S.I.S.c ; Brant A. Inman ; M.D. ; M.S.a ; brant.inman@duke.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Bladder cancer ; Urothelial carcinoma ; Deep venous thrombosis ; Pulmonary ; Embolism ; Venous thromboembolism ; Systemic therapy ; Chemotherapy
- 刊名：Urologic Oncology: Seminars and Original Investigations
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：34
- 期：9
- 页码：407-414
- 全文大小：575 K
文摘
- •
VTE in patients undergoing systemic therapy for urothelial carcinoma is unknown.
- •
We found that VTE occurs in 5.4% of these patients.
- •
Systemic agent class, country of origin, and history of radiation affect VTE rate.
- •
Antiangiogenics and anti-ErbB classes are associated with highest VTE rates.
- •
History of radiation is associated with higher VTE rates.